Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Relative Bioavailability of Eratrectinib (VC004) in Healthy Adults
NCT06529445Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eratrectinib in NTRK fusion-positive solid tumor (3 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Observed Plasma Concentration and 1 more. Started Jul 2024; status: completed.
02
Drugs
eratrectinib
03
Conditions
NTRK fusion-positive solid tumor
Beyond the preview
Go deeper on NCT06529445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529445.